Connect Biopharma announced positive topline results from its Phase 2 study of rademikibart for acute asthma exacerbations, showing a statistically significant improvement in lung function and a 66% reduction in treatment failure rates. While the primary endpoint of treatment failure did not reach statistical significance due to a lower-than-projected overall failure rate, the strong efficacy signals and safety profile position the drug for a Phase 3 program, potentially creating significant value for the company.
Connect Biopharma released interim topline data from its Phase 2 Seabreeze STAT asthma trial for rademikibart, an anti-IL-4Rα antibody. The key findings include a statistically significant 130mL greater improvement in FEV1 (lung function) compared to placebo at Day 7, and a 66% reduction in treatment failure rates over 28 days, although this latter endpoint did not achieve statistical significance due to a lower overall event rate than anticipated. This is a significant positive development for CNTB as it provides a clear roadmap for a Phase 3 program and suggests a strong potential for rademikibart to become a new standard of care for acute asthma exacerbations, a market with substantial unmet needs and economic burden. Traders should see this as a strong validation of the drug's potential, with short-term positive sentiment and long-term growth prospects if Phase 3 is successful and regulatory approval is achieved. The upcoming COPD trial results later this month could further de-risk the asset.